Novartis AG (NYSE:NVS) Shares Acquired by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC grew its position in Novartis AG (NYSE:NVS) by 2.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,975 shares of the company’s stock after acquiring an additional 314 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Novartis were worth $1,669,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Continuum Advisory LLC increased its position in Novartis by 10.3% in the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company’s stock worth $99,000 after buying an additional 95 shares during the period. Intergy Private Wealth LLC increased its position in Novartis by 3.9% in the first quarter. Intergy Private Wealth LLC now owns 2,757 shares of the company’s stock worth $307,000 after buying an additional 104 shares during the period. Keudell Morrison Wealth Management increased its position in Novartis by 3.8% in the first quarter. Keudell Morrison Wealth Management now owns 2,828 shares of the company’s stock worth $315,000 after buying an additional 104 shares during the period. D Orazio & Associates Inc. increased its position in Novartis by 2.9% in the first quarter. D Orazio & Associates Inc. now owns 3,795 shares of the company’s stock worth $423,000 after buying an additional 108 shares during the period. Finally, Opal Wealth Advisors LLC increased its position in Novartis by 4.7% in the first quarter. Opal Wealth Advisors LLC now owns 2,515 shares of the company’s stock worth $280,000 after buying an additional 112 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, BNP Paribas raised Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Novartis currently has an average rating of “Hold” and a consensus price target of $123.67.

Novartis Trading Down 0.3%

Shares of NVS stock opened at $121.80 on Wednesday. The stock has a 50-day simple moving average of $115.44 and a 200 day simple moving average of $109.33. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $124.45. The stock has a market capitalization of $257.29 billion, a P/E ratio of 19.03, a P/E/G ratio of 1.68 and a beta of 0.59. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.56.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.16. Novartis had a return on equity of 39.44% and a net margin of 24.70%. The business had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $12.92 billion. During the same quarter last year, the business posted $1.80 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. On average, sell-side analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.